Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

72.77 +1.54 (+2.16%)
Official Closing Price Updated: 4:10 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,015,004
Open 70.32
Bid (Size) 72.77 (1)
Ask (Size) 73.00 (5)
Prev. Close 71.23
Today's Range 69.80 - 72.88
52wk Range 62.90 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 2.69%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Bristol Myers Squibb Q4 Earnings And Revenues Surpass Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.82 per share. 
Via Talk Markets

Performance

YTD
+0.71%
+0.71%
1 Month
+0.71%
+0.71%
3 Month
-6.04%
-6.04%
6 Month
-0.30%
-0.30%
1 Year
+11.63%
+11.63%

More News

Read More
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range
Via Benzinga
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook
Via Investor's Business Daily
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
A Preview Of Bristol-Myers Squibb's Earnings
Via Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For February 01
Via Benzinga
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Via The Motley Fool
2 Top Dividend Stocks to Buy in 2023 and Hold Forever
Via The Motley Fool
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Via The Motley Fool
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
From Bristol Myers Squibb
Via Business Wire
3 Buffett-Type Stocks to Buy Right Now
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Via Talk Markets
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen’s Commitment of $8 Million
From Bristol Myers Squibb
Via Business Wire
5 Stocks You Can Confidently Invest $500 in Right Now
Via The Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
Via Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug
Via The Motley Fool
7 Dividend-Paying Large-Cap Stocks to Buy in January
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.